ERT’s propriety methodology, EPQT, was utilized in the IQ-CSRC study which proved that the desired objectives of a successful TQT study can be achieved  from SAD/MAD studies – a study which led to the revision of the ICH E14 Guidelines.  

Download our white paper to discover how adopting an EPQT methodology can:

  • Make earlier assessments of cardiac safety to better minimize risk, position, prioritize, and resource programs
  • Ensure that promising drugs are not inappropriately eliminated because of inaccurate cardiac safety data
  • Introduce new drugs to the marketplace earlier
  • Eliminate unnecessary late stage TQT studies

By submitting this form you are consenting to receive digital communications from ERT and you agree to our Privacy Policy and Website Terms of Use.